Oct 16, 2025
Lilly confirms date and conference call for third-quarter 2025 financial results announcement
Oct 15, 2025
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
Oct 13, 2025
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Oct 07, 2025
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Sep 26, 2025
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
Sep 25, 2025
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Sep 25, 2025
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
Sep 23, 2025
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 17, 2025
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Sep 17, 2025
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
Sep 16, 2025
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
Sep 11, 2025
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
Sep 09, 2025
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Sep 09, 2025
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
Sep 08, 2025
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
Sep 04, 2025
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
Aug 27, 2025
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
Aug 26, 2025
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
Aug 22, 2025
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
Aug 20, 2025
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience